Literature DB >> 22644089

Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.

Mohammed A Omair1, Khalid A Alnaqbi, Peter Lee.   

Abstract

Tumor necrosis factor inhibitors (TNFI) are novel therapies used to treat ankylosing spondylitis (AS). Demyelinating disease is a rare but serious complication of TNFI. We report a patient with a case of AS who developed demyelinating disease secondary to TNFI and was treated successfully with rituximab.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22644089     DOI： 10.1007/s10067-012-2002-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  20 in total

1.  Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis.

Authors:  Heiner Appel; Maren Kuhne; Simone Spiekermann; Harald Ebhardt; Zarko Grozdanovic; Dorothee Köhler; Marc Dreimann; Axel Hempfing; Martin Rudwaleit; Harald Stein; Peter Metz-Stavenhagen; Joachim Sieper; Christoph Loddenkemper
Journal:  Arthritis Rheum       Date:  2006-09

2.  Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis.

Authors:  J W Prineas; R G Wright
Journal:  Lab Invest       Date:  1978-04       Impact factor: 5.662

3.  Immunoglobulin-containing cells in multiple-sclerosis plaques.

Authors:  M M Esiri
Journal:  Lancet       Date:  1977-09-03       Impact factor: 79.321

4.  Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging.

Authors:  M Bollow; T Fischer; H Reisshauer; M Backhaus; J Sieper; B Hamm; J Braun
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

5.  Rituximab for secondary progressive multiple sclerosis: a case series.

Authors:  Paulus S Rommer; Robert Patejdl; Alexander Winkelmann; Reiner Benecke; Uwe K Zettl
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

Review 6.  Demyelination and inhibition of tumor necrosis factor (TNF).

Authors:  M D Magnano; W H Robinson; M C Genovese
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

7.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

8.  Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Authors:  Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

9.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

10.  Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis.

Authors:  Heiner Appel; Christoph Loddenkemper; Zarko Grozdanovic; Harald Ebhardt; Marc Dreimann; Axel Hempfing; Harald Stein; Peter Metz-Stavenhagen; Martin Rudwaleit; Joachim Sieper
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156
View more
  3 in total

Review 1.  Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon.

Authors:  Rbab Taha; Hadeel El-Haddad; Abdulqader Almuallim; Fatma Alshaiki; Elaf Obaid; Hani Almoallim
Journal:  Open Access Rheumatol       Date:  2017-12-15

2.  Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.

Authors:  Ritwik Ghosh Md; Devlina Roy; Moisés León-Ruiz; Shambaditya Das; Souvik Dubey; Julián Benito-León
Journal:  Qatar Med J       Date:  2022-07-07

Review 3.  B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis.

Authors:  Rick Wilbrink; Anneke Spoorenberg; Gwenny M P J Verstappen; Frans G M Kroese
Journal:  Int J Mol Sci       Date:  2021-12-11       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.